Haemonetics Corporation (HAE)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Haemonetics Corporation (HAE)
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Key Insights
Critical company metrics and information
Share Price
$83.51Market Cap
$4.19 BillionTotal Outstanding Shares
50.22 Million SharesTotal Employees
3,657Dividend
No dividendIPO Date
May 9, 1991SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.haemonetics.com
Historical Stock Splits
If you bought 1 share of HAE before December 3, 2012, you'd have 2 shares today.
Execution Date | Split Amount |
---|---|
December 3, 2012 | 2-for-1 |
Cash Flow Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $304.81 Million |
Net Cash Flow From Investing Activities, Continuing | $-444.56 Million |
Net Cash Flow | $-51.72 Million |
Net Cash Flow From Financing Activities, Continuing | $304.81 Million |
Net Cash Flow From Investing Activities | $-444.56 Million |
Net Cash Flow, Continuing | $-54.80 Million |
Exchange Gains/Losses | $3.08 Million |
Net Cash Flow From Operating Activities, Continuing | $84.94 Million |
Net Cash Flow From Operating Activities | $84.94 Million |
Income Statement
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit, Deferred | $-15.16 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Selling, General, and Administrative Expenses | $448.59 Million |
Depreciation and Amortization | $109.52 Million |
Net Income/Loss Available To Common Stockholders, Basic | $123.81 Million |
Basic Average Shares | $101.72 Million |
Diluted Average Shares | $102.85 Million |
Operating Income/Loss | $167.37 Million |
Benefits Costs and Expenses | $1.20 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Gross Profit | $716.13 Million |
Diluted Earnings Per Share | $2.41 |
Income/Loss From Continuing Operations After Tax | $123.81 Million |
Net Income/Loss Attributable To Parent | $123.81 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $123.81 Million |
Operating Expenses | $548.76 Million |
Cost Of Revenue | $645.09 Million |
Revenues | $1.36 Billion |
Income/Loss From Continuing Operations Before Tax | $158.86 Million |
Research and Development | $60.10 Million |
Income Tax Expense/Benefit | $35.05 Million |
Costs And Expenses | $1.20 Billion |
Basic Earnings Per Share | $2.44 |
Balance Sheet
September 29, 2023 to September 28, 2024
Metric | Value |
---|---|
Equity | $878.85 Million |
Current Assets | $955.90 Million |
Noncurrent Assets | $1.57 Billion |
Other Current Assets | $573.80 Million |
Inventory | $382.11 Million |
Other Non-current Assets | $781.01 Million |
Accounts Payable | $69.24 Million |
Noncurrent Liabilities | $1.37 Billion |
Liabilities And Equity | $2.53 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Intangible Assets | $487.84 Million |
Equity Attributable To Parent | $878.85 Million |
Fixed Assets | $300.48 Million |
Current Liabilities | $273.95 Million |
Wages | $49.30 Million |
Liabilities | $1.65 Billion |
Other Current Liabilities | $155.40 Million |
Assets | $2.53 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Haemonetics Corporation (HAE)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.